ERBB2 and breast carcinoma: Trastuzumab, a classical anti-HER-2 mAb, inhibits the growth of HER-2 positive breast cancer cells through specific binding with HER-2 receptors,95 and plays a leading role in adjuvant therapy and metastatic therapy of breast cancer.